Latest On Kissei Pharmaceutical Co., Ltd (KSPHF):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2021-03-30 06:18 EST | Dividend | A dividend of $27 has been announced on May 12, 2020. It will be paid Nov 30, -0001 with an ex-dividend date of Mar 30, 2021. | Neutral |  |
| 2021-02-03 14:11 EST | Financials | Company financials have been released. | Neutral | |
| 2020-12-04 18:36 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-27 00:04 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-17 14:26 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-07 19:14 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-06 10:16 EST | Financials | Company financials have been released. | Neutral | |
| 2020-10-08 20:10 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-26 16:05 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-17 08:43 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-14 12:09 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-07 11:14 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-06 15:48 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-04 19:04 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-31 11:29 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-31 03:48 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 19:58 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 07:57 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 00:11 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-28 16:48 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-27 23:09 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-27 15:46 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-09 11:58 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-09 06:55 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-01 19:37 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-01 03:29 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-25 06:50 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-19 15:31 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-14 07:41 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-12 09:14 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-05 14:58 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-03 18:52 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-27 08:18 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-21 04:01 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-07 03:16 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-06 08:38 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-02 23:09 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-01 19:28 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-30 06:57 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-23 06:52 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-23 03:06 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-20 07:15 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-16 19:02 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-16 15:01 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-16 10:43 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-16 02:51 EST | Financials | Company financials have been released. | Neutral | |
About Kissei Pharmaceutical Co., Ltd (KSPHF):
Kissei Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products primarily in Japan. It offers Urief and Urief OD tablets for the treatment of dysuria; Glufast, Glubes, and Marizev tablets for type 2 diabetes; Darbepoetin Alfa BS and Epoetin Alfa BS injections for the treatment of renal anemia; Beova tablets for overactive bladder treatment; P-TOL chewable tablets for treating hyperphosphatemia; and Minirin Melt OD tablets for nocturia due to nocturnal polyuria in males, central diabetes insipidus, and nocturnal enuresis resulted from decrease of urine osmolality. The company's products in pipeline include KPS-0373 that has completed Phase III clinical trial to treat spinocerebellar ataxia; CCX168, which has completed Phase III clinical trial for the treatment of microscopic polyangiitis and granulomatosis with polyangiitis; AJM300, which is in Phase III clinical trial to treat ulcerative colitis; R788 that is in Phase III clinical trial to treat chronic idiopathic thrombocytopenic purpura; and MR13A9, which is in Phase III clinical trial to treat uremic pruritus in dialysis patients. It is also developing KLH-2109 for treating endometriosis and uterine fibroids; KDT-3594 for the treatment of Parkinson's disease; Silodosin for dysuria associated with benign prostatic hyperplasia; Mitiglinide for type 2 diabetes mellitus; and Bedoradrine for the treatment of acute exacerbation of asthma. In addition, it develops and sells protein controlled and energy supply foods; and purchases and sells related materials, as well as offers system development and information processing, construction contracting, equipment and facility management, and information gathering and development support services. The company was formerly known as Kissei Yakuhin Kogyo Co., Ltd. and changed its name to Kissei Pharmaceutical Co., Ltd. in October 1964. The company was founded in 1946 and is headquartered in Matsumoto, Japan.
General
- Name Kissei Pharmaceutical Co., Ltd
- Symbol KSPHF
- Type Common Stock
- Exchange PINK
- Currency USD
- Country USA
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- Full Time Employees 1,892
- Fiscal Year EndMarch
- Web URLhttp://www.kissei.co.jp
Valuation
- Trailing PE 19.84
- Price/Sales (Trailing 12 Mt.) 1.69
- Price/Book (Most Recent Quarter) 0.53
- Enterprise Value Revenue 0.01
- Enterprise Value EBITDA 0.07
Financials
- Most Recent Quarter 2020-12-31
- Profit Margin 9%
- Return on Assets 1%
- Return on Equity 3%
- Revenue Per Share $0
- Gross Profit 34.91 billion
- Quarterly Earnings Growth 17.1%
Highlights
- Market Capitalization 1.03 billion
Share Statistics
- Shares Outstanding 46.72 million
- Shares Float 40.85 million
- % Held by Insiders 2386%
- % Held by Institutions 27.61%
Technicals
- Beta 0.61
- 52 Week High $25.5
- 52 Week Low $19.7
- 50 Day Moving Average 22.2
- 200 Day Moving Average 21.65
Dividends
- Forward Annual Dividend Rate $0.52
- Forward Annual Dividend Yield 2.33%
- Payout Ratio 3084%
- Dividend Date N/A
- ExDividend Date 2020-09-29
- Dividend Per Share $0.52
- Dividend Yield 0%
Kissei Pharmaceutical Co., Ltd (KSPHF) Dividend Calendar:
Kissei Pharmaceutical Co., Ltd pays out 3084% of its earnings out as a dividend.
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Kissei Pharmaceutical Co., Ltd (KSPHF) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-12-31 | 2020-12-31 | $N/A | $0.42 | ||
| 2020-09-30 | 2020-12-31 | $N/A | $0.42 | $15.00 | -97.18% |
| 2020-06-30 | 2020-09-30 | $N/A | $0.54 | $17.05 | -96.82% |
| 2020-03-31 | 2020-06-30 | $N/A | $0.34 | ||
| 2019-12-31 | 2020-03-31 | $17 billion | -$0.14 | ||
| 2019-09-30 | 2019-12-31 | $15.45 billion | $0.27 | ||
| 2019-06-30 | 2019-09-30 | $16.11 billion | $0.03 | $25.70 | -99.89% |
| 2019-03-31 | 2019-06-30 | $17.04 billion | $0.40 | ||
| 2018-12-31 | 2019-03-31 | $19.59 billion | $0.23 | ||
| 2018-09-30 | 2018-12-31 | $17.81 billion | $0.18 | ||
| 2018-06-30 | 2018-09-30 | $17.85 billion | $0.11 | $41.60 | -99.73% |
| 2018-03-31 | 2018-06-30 | $17.22 billion | $0.53 | ||
| 2017-12-31 | 2018-03-31 | $20.2 billion | $0.20 | ||
| 2017-09-30 | 2017-12-31 | $17.74 billion | $0.69 | ||
| 2017-06-30 | 2017-09-30 | $18.85 billion | $0.40 | ||
| 2017-03-31 | 2017-06-30 | $17.1 billion | $0.39 | ||
| 2016-12-31 | 2017-03-31 | $0.13 | |||
| 2016-09-30 | 2016-12-31 | $0.56 | |||
| 2016-06-30 | 2016-09-30 | $0.21 | $33.70 | -99.37% | |
| 2016-03-31 | 2016-06-30 | $0.56 | |||
| 2015-12-31 | 2016-03-31 | -$0.12 | $0.00 | ||
| 2015-09-30 | 2015-12-31 | $0.83 | $0.00 | ||
| 2015-06-30 | 2015-09-30 | $0.29 | $49.41 | -99.42% | |
| 2015-03-31 | 2015-06-30 | $0.38 | $0.00 | ||
| 2014-12-31 | 2015-03-31 | -$0.05 | $34.20 | -100.14% | |
| 2014-09-30 | 2014-12-31 | $0.49 | $0.00 | ||
| 2014-06-30 | 2014-09-30 | $0.40 | $0.00 | ||
| 2014-03-31 | 2014-06-30 | $0.44 | $0.00 | ||
| 2013-12-31 | 2014-03-31 | $0.07 | $0.00 | ||
| 2013-09-30 | 2013-12-31 | $0.91 | $0.00 | ||
| 2013-06-30 | 2013-09-30 | $0.27 | $0.00 | ||
| 2013-03-31 | 2013-06-30 | $0.48 | $0.00 | ||
| 2012-12-31 | 2013-03-31 | $0.13 | $0.00 | ||
| 2012-09-30 | 2012-12-31 | $0.57 | $0.00 | ||
| 2012-06-30 | 2012-09-30 | $0.09 | $0.00 | ||
| 2012-03-31 | 2012-06-30 | $0.35 | $0.00 | ||
| 2011-12-31 | 2012-03-31 | $0.19 | $0.00 | ||
| 2011-09-30 | 2011-12-31 | $0.38 | $0.00 | ||
| 2011-06-30 | 2011-09-30 | $0.28 | $0.00 | ||
| 2011-03-31 | 2011-06-30 | $0.31 | $0.00 | ||
| 2010-12-31 | 2011-03-31 | $0.17 | $0.00 | ||
| 2010-09-30 | 2010-12-31 | $0.41 | $0.00 |
Kissei Pharmaceutical Co., Ltd (KSPHF) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Research Development | N/A | N/A | N/A | N/A | N/A |
| Income Before Tax | N/A | N/A | N/A | N/A | 1.92 billion |
| Selling General Administrative | N/A | N/A | N/A | N/A | 8.7 billion |
| Gross Profit | N/A | N/A | N/A | N/A | 9.1 billion |
| Ebit | N/A | N/A | N/A | N/A | 1.93 billion |
| Operating Income | N/A | N/A | N/A | N/A | 405 million |
| Income Tax Expense | 769 million | 842 million | 468 million | 542 million | 509 million |
| Total Revenue | N/A | N/A | N/A | N/A | 17 billion |
| Cost of Revenue | N/A | N/A | N/A | N/A | 7.9 billion |
| Total Other Income Expense Net | N/A | N/A | N/A | N/A | 1.52 billion |
| Net Income From Continuing Operations | N/A | N/A | N/A | N/A | 1.41 billion |
| Net Income Applicable to Common Shares | 2.04 billion | 2.67 billion | 1.73 billion | -725 million | 1.39 billion |
Balance Sheet:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Total Liabailities | N/A | N/A | N/A | N/A | 34.88 billion |
| Total Stockholder Equity | N/A | N/A | N/A | N/A | 193.91 billion |
| Other Current Liabilities | 8.46 billion | 6.82 billion | N/A | N/A | 5.21 billion |
| Total Assets | N/A | N/A | N/A | N/A | 229.3 billion |
| Common Stock | 24.36 billion | 24.36 billion | 24.36 billion | 24.36 billion | 24.36 billion |
| Other Current Assets | 4.08 billion | 4 billion | N/A | N/A | 5.18 billion |
| Retained Earnings | 110.43 billion | 109.64 billion | 106.97 billion | 106.46 billion | 107.19 billion |
| Other Liabilities | 29.57 billion | 31.8 billion | 30.73 billion | 21.79 billion | 19.8 billion |
| Other Assets | 540 million | 555 million | 684 million | 715 million | 516 million |
| Cash | N/A | N/A | N/A | N/A | 32.95 billion |
| Total Current Liabilities | 18.26 billion | 15.64 billion | N/A | N/A | 13.17 billion |
| Other Stockholder Equity | 66.68 billion | 71.9 billion | 70.11 billion | 49.03 billion | 49.75 billion |
| Property, Plant & Equipment | 24.11 billion | 24.27 billion | 24.41 billion | 24.61 billion | 24.71 billion |
| Total Current Assets | 94.52 billion | 91.6 billion | N/A | N/A | 97.53 billion |
| Long Term Investments | N/A | N/A | N/A | N/A | 105.1 billion |
| Net Tangible Assets | 212.44 billion | 217 billion | 212.54 billion | 190.95 billion | 192.46 billion |
| Short Term Investments | N/A | N/A | N/A | N/A | 23.04 billion |
| Long Term Debt | N/A | N/A | N/A | N/A | 1.92 billion |
| Inventory | 16.66 billion | 16.93 billion | N/A | N/A | 13.31 billion |
| Accounts Payable | 7.25 billion | 5.34 billion | N/A | N/A | 4.27 billion |
Kissei Pharmaceutical Co., Ltd (KSPHF) Chart:
Kissei Pharmaceutical Co., Ltd (KSPHF) News:
Below you will find a list of latest news for Kissei Pharmaceutical Co., Ltd (KSPHF) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Kissei Pharmaceutical Co., Ltd (KSPHF) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Kissei Pharmaceutical Co., Ltd (KSPHF) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|